• The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
  • This web site is a service of Prostate Cancer International.

    pcai_cmyk

  • Other PCI web sites

  • The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

    • Perspective Confidentiality Disclosure Reliability Courtesy

FDA to rule on approval of Provenge by May 2010

According to a Reuters report this morning, the U.S. Food and Drug Administration has advised Dendreon that the company can expect a ruling on the approval of sipuleucel-T (Provenge), the company’s investigational immunotherapeutic agent for the treatment of hormone-refractory prostate cancer, on or before May 1, 2010.

3 Responses

  1. I’m looking foward Provenge’s approval. My father needs it.

    Thank you!

  2. Based on my research there is still the possibility of Provenge going to a panel.

  3. Dear Mr. Favus:

    It is certainly true that, in theory, FDA could convene another advisory board meeting to address the application to approve Provenge. However, frankly, since they are required to rule on this approve within the next 14 days, it would seem extraordinary to me that, if they had any intention of convening such a panel, they had not announced it by now.

Leave a Reply